In addition, more insights in RECQL4‐driven signalling pathways in large patient cohorts under ICI therapy are needed to better understand the impact of REQCL4 on cancer‐related modulators that influence disease progression and ICI response. This evidence concerns the gene RECQL4 and cancer.